{"product_id":"american-society-of-hematology-annual-meeting-and-exposition-2025","title":"American Society of Hematology Annual Meeting and Exposition 2025","description":"\u003cul\u003e\n  \u003cli\u003eInclude:  videos +  pdf, size:  GB\u003c\/li\u003e\n  \u003cli\u003eTarget Audience: hematologist-oncologists, pathologists\u003c\/li\u003e\n  \u003cli\u003eSample video: contact me for sample video\u003c\/li\u003e\n  \u003cli\u003eInformation:\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eASH 2025: THE 67TH ANNUAL MEETING \u0026amp; EXPOSITION\u003c\/p\u003e\n\u003cp\u003e“Defining the Future of Blood: Gene Therapy, Immunotherapy \u0026amp; Beyond”\u003c\/p\u003e\n\u003cp\u003eGeneral Information\u003c\/p\u003e\n\u003cp\u003eWelcome to the “Super Bowl” of Hematology. The ASH Annual Meeting is the global benchmark where practice-changing data is released. If it happens in blood, it happens here.\u003c\/p\u003e\n\u003cp\u003eThe 2025 edition in New Orleans marks a pivotal shift: we move from “experimental” gene editing to commercial reality. This course is not just about the science; it is about the logistics of cure. From the latest CAR-T constructs for solid tumors to the real-world implementation of CRISPR for Sickle Cell Disease, this curriculum defines the standard of care for the next decade.\u003c\/p\u003e\n\u003cp\u003eFormat: Scientific Plenary Sessions + Education Programs + Satellite Symposia.\u003c\/p\u003e\n\u003cp\u003eTarget Audience\u003c\/p\u003e\n\u003ch3\u003eThis syllabus is the mandatory annual update for:\u003c\/h3\u003e\n\u003cp\u003eHematologist-Oncologists: Who need to decide between Bispecific Antibodies and CAR-T therapy for their relapsed Myeloma and Lymphoma patients.\u003c\/p\u003e\n\u003cp\u003eTransplant Physicians: Managing the toxicities of cellular therapies (CRS\/ICANS) in an outpatient setting.\u003c\/p\u003e\n\u003cp\u003eGeneral Practitioners\/Hospitalists: Who need to recognize the “red flags” of hematologic emergencies and manage the long-term survivors of gene therapy.\u003c\/p\u003e\n\u003cp\u003eLearning Objectives\u003c\/p\u003e\n\u003ch3\u003eBy analyzing the 2025 Late-Breaking Abstracts, participants will be able to:\u003c\/h3\u003e\n\u003cp\u003eRevolutionize Myeloma Care: Apply the 2025 algorithms for Quadruplet Therapy in newly diagnosed Multiple Myeloma and sequence BCMA-targeted agents in relapse.\u003c\/p\u003e\n\u003cp\u003eImplement Gene Editing: Navigate the referral and management pathways for Casgevy (Exa-cel) and Lyfgenia in Sickle Cell Disease and Beta-Thalassemia.\u003c\/p\u003e\n\u003cp\u003eManage Hemophilia: Transition patients from factor replacement to Gene Therapy (Hemgenix\/Roctavian) and non-factor replacement therapies.\u003c\/p\u003e\n\u003cp\u003eCourse Topics \u0026amp; Tracks (2025 Predictions)\u003c\/p\u003e\n\u003cp\u003eThe curriculum focuses on the highest-yield clinical areas.\u003c\/p\u003e\n\u003cp\u003eTOPIC 1: The Myeloma \u0026amp; Lymphoma Revolution\u003c\/p\u003e\n\u003cp\u003eBispecifics vs. CAR-T: The “Great Debate.” When to use “off-the-shelf” antibodies (Teclistamab, Talquetamab) versus autologous cell therapy.\u003c\/p\u003e\n\u003cp\u003eTOPIC 2: Leukemia \u0026amp; Myeloid Malignancies\u003c\/p\u003e\n\u003cp\u003eAML Updates: The rise of “Triplet” therapies (HMA + Venetoclax + Novel Agent) for the unfit patient.\u003c\/p\u003e\n\u003cp\u003eMDS Classification: Mastering the new WHO vs. ICC classifications—it’s not just “MDS” anymore; it’s molecularly defined.\u003c\/p\u003e\n\u003cp\u003eTOPIC 3: Non-Malignant Hematology (Red Cell \u0026amp; Coag)\u003c\/p\u003e\n\u003cp\u003eITP \u0026amp; TTP: New agents targeting the complement system and FcRn inhibitors.\u003c\/p\u003e\n\u003cp\u003eTOPIC 4: Immuno-Oncology \u0026amp; Toxicity Management\u003c\/p\u003e\n\u003cp\u003eCRS \u0026amp; ICANS: 2025 Protocols for managing Cytokine Release Syndrome and Neurotoxicity without admitting every patient to the ICU.\u003c\/p\u003e\n\u003cp\u003eInfection Prevention: Prophylaxis strategies for the profoundly immunosuppressed patient on B-cell maturation antigen (BCMA) therapy.\u003c\/p\u003e","brand":"Medicalcoursespro","offers":[{"title":"Default Title","offer_id":46405794463940,"sku":null,"price":195.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0751\/7644\/4100\/files\/American-Society-of-Hematology-Annual-Meeting-and-Exposition-2025.png?v=1784216262","url":"https:\/\/medicalcoursespro.com\/products\/american-society-of-hematology-annual-meeting-and-exposition-2025","provider":"Medicalcoursespro","version":"1.0","type":"link"}